Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

Bullboard Posts
Post by elgin1on Oct 16, 2019 1:50pm
102 Views
Post# 30236930

News

NewsSignificance of c peptide produced during fasting and elevated during meal consumption is very important. It reinforces or confirms the biofeedback loop that is inherently present in a normal healthy human being.  This means the islet cells turn on and off by themselves to produce insulin as the blood sugars fluctuate.  In my opinion this is a significant breakthrough.  I think these results are approxiamtely 6 months post implantation (nr failed to mention this). 

Next catalyst will other patients showing similar results. Finally they need to solve the immunosuppression issue.   If they can remove the need for immunosuppressive drugs, will be one step closer for a cure for diabetes.

The sp trading in pennies is irrelevent. The larger picture is  potential for a cure and the market size of diabetes. Only time will tell.  Sernova is the leader so far. Lets see what  results we get in the next 6 months.

Elgin
Bullboard Posts